DENVER, Colo. (247marketnews.com) — Monday’s market is serving up strong a mix of AI moves, Biotech catalysts, Crypto craze, and aggressive corporate turnarounds. Among the names attracting attention are Innovative Eyewear (NASDAQ:LUCY), Picard Medical (NYSEAMERICAN:PMI), NeOnc Technologies Holdings (NASDAQ:NTHI), CorMedix (NASDAQ:CRMD), BTC Digital (NASDAQ:BTCT), Expion Energy (NASDAQ:XPON) and Sadot Group Inc. (NASDAQ:SDOT). Meanwhile, Zcash (CRYPTO:ZEC) is adding a major cryptocurrency catalyst to the mix as Grayscale prepares for a potential U.S. ETF launch.
Innovative Eyewear: Smart Glasses Move from Gadget to Growth Story
Innovative Eyewear (NASDAQ:LUCY) is pushing aggressively into the expanding AI-smart-glasses market. The company announced a strategic alliance with HTC to commercialize HTC’s VIVE Eagle smart eyewear in the United States beginning in September. LUCY plans to sell the glasses through Lucyd.co with U.S.-based prescription-lens fulfillment.
The HTC relationship is particularly interesting because LUCY says VIVE Eagle is the first partner-developed product it has chosen to offer through its flagship store. CEO Harrison Gross said, “I truly feel this smartglass is superior to other camera glass options available today.” The glasses are entering a market increasingly shaped by AI assistants, cameras, voice interfaces and growing consumer interest in hands-free computing.
LUCY is also expanding distribution beyond consumer smart glasses. The company announced that Lucyd Armor products are entering a test rollout across more than 150 stores of one of the largest U.S. big-box retailers, with sales expected to begin in October. The retailer has not been named. That combination of HTC hardware, prescription fulfillment, AI functionality and national retail distribution, gives LUCY several potential growth vectors at once.
Picard Medical: Artificial Heart Technology Meets a Fresh Financial Catalyst
Picard Medical’s (NYSEAMERICAN:PMI) story may be its next-generation Emperor Total Artificial Heart. Picard said it completed acute in-vivo implant studies of the latest Emperor iteration and subsequently presented the platform’s integrated architecture at the IEEE Engineering in Medicine and Biology Society conference. Management has previously said it could seek approval as early as 2028, although regulatory timing remains uncertain.
Interim CEO Richard Fang recently stated, “Revenue growth and the improvement in gross profitability reflect progress in our core business.”
NeOnc Technologies Holdings: A Brain-Cancer Catalyst Puts NEO100 in the Spotlight
NeOnc (NASDAQ:NTHI) is riding one of the more consequential clinical catalysts in the group. On August 12, the company reported positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study reported six-month progression-free survival of 48.9% versus a prespecified 20% historical benchmark, with a reported p-value of 0.0047. NeOnc said it plans to request a Type B FDA meeting to discuss a potential registrational pathway.
The potential importance is straightforward: recurrent high-grade glioma is an area of substantial unmet medical need, and NeOnc is positioning NEO100 as a CNS-focused therapy designed to overcome challenges associated with delivering treatments across the blood-brain barrier. The company is now moving from a clinical readout toward the regulatory strategy that could determine how quickly the program advances.
Insider buying has added another layer to the trading narrative. Chairman and CEO Amir Heshmatpour has disclosed purchases of NTHI shares, including additional buying following the Phase 2a catalyst, while Thomas Chen, an NTHI Board Director, who is a board-certified neurosurgeon and the Director of Surgical Neuro-Oncology at USC, reported purchases of 33,787 shares at $3.8477 on August 14 and another 2,472 shares at $4.0445 on August 17. Those transactions bring his direct holdings to 583,531 shares, according to the filing information provided.
CorMedix: DefenCath Is Turning a Biotech Story into a Revenue Story
CorMedix (NASDAQ:CRMD) stands apart from the earlier-stage biotech names because it is already producing substantial commercial revenue. Second-quarter results showed DefenCath contributing $66.1 million in net revenue, while the acquired Melinta portfolio contributed another $35.8 million. CorMedix also reported second-quarter EPS of $0.33 basic and $0.29 diluted.
The company has continued expanding its commercial footprint. CorMedix signed a new multi-year DefenCath supply agreement with a large dialysis operator, bringing its contract footprint to all five of the largest U.S. dialysis providers. The new customer has begun ordering DefenCath and plans a third-quarter pilot, potentially giving the company another avenue for adoption growth.
The pipeline adds another potential catalyst. CorMedix and development partner Mundipharma expect to submit an FDA supplemental application for an expanded REZZAYO indication in the third quarter, with potential FDA action in the first half of 2027 if the application is accepted. Meanwhile, management maintained 2026 revenue guidance of $325 million to $345 million and raised adjusted EBITDA guidance to $125 million to $140 million. That combination of commercial execution and pipeline optionality makes CRMD one of the more interesting growth stories among Monday’s biotech movers.
BTC Digital: The Bitcoin Miner Wants a Seat at the AI Infrastructure Table
BTC Digital (NASDAQ:BTCT) is moving another step toward bringing its Georgia cryptocurrency infrastructure online. The company says construction of its 10MW Georgia facility is complete and that the site is approaching deployment readiness, with mining machines expected to be deployable within approximately two months. At full deployment, BTCT says the facility is designed to support approximately 900,000 TH/s, or 900 PH/s, of theoretical computing capacity.
The more intriguing part of the story is that BTCT increasingly wants investors to think beyond Bitcoin mining. The company has been pursuing a “dual-engine” strategy combining cryptocurrency computing with AI infrastructure. Earlier this year it also announced an Alberta project designed around an “Energy-to-Compute” model, initially using natural gas-powered infrastructure for Bitcoin mining while exploring future AI and data-center applications.
That makes the Georgia project a potential bridge between two booming but very different markets. Bitcoin mining offers immediate computing demand, while AI infrastructure could ultimately offer a higher-value use for power and data-center capacity. BTCT has also brought in AI-focused leadership to accelerate customer acquisition and business development. The opportunity is substantial, but investors should distinguish planned capacity from actual revenue-generating utilization.
$ZEC: The Privacy Coin Is Suddenly Back in the Spotlight
Zcash (CRYPTO:ZEC) has become one of the market’s most explosive cryptocurrency stories as traders anticipate a major U.S. ETF catalyst. ZEC recently reached its highest level since 2018, with Yahoo Finance reporting a move to approximately $855 during the weekend rally. The move followed Grayscale’s progress toward converting its existing Zcash Trust into a U.S.-listed ETF.
Grayscale said on August 21 that the trust’s shares were anticipated to begin trading on NYSE Arca on or about August 25 under the ticker ZCSH, subject to regulatory approvals. The proposed product is expected to be renamed The Zcash ETF. The potential launch would provide a much more conventional brokerage-market access point for ZEC exposure.
Sadot Group: Debt Deals and an AI Trading Pivot Fuel a Wild Rally
Sadot (NASDAQ:SDOT) has become another high-volatility name as investors digest a combination of debt restructuring and an AI-focused trading strategy. Shares surged sharply in recent sessions, with premarket trading on Monday showing another major move as investors focused on the company’s progress in reducing debt.
The company has been restructuring its capital structure while promoting TradeOS, an AI-powered trading platform. Recent reports said TradeOS executed its initial commercial deals in July and generated approximately $1 million in preliminary gross revenue. Meanwhile, Sadot has been using equity transactions to address outstanding debt obligations, creating a very different capital-structure story from earlier in the year.
But SDOT may be the ultimate reminder that momentum cuts both ways. The stock has experienced enormous swings, including a severe July collapse and multiple trading halts following a short-seller report. More recently, the shares have rebounded dramatically as traders focused on debt reduction, the AI pivot and the company’s relatively small share count. For momentum traders, that creates explosive potential; for fundamental investors, it also creates an unusually high-risk setup.
Expion Energy: From Batteries to a Louisiana Oil-and-Gas Bet
Expion Energy (NASDAQ:XPON) may have made Monday’s most dramatic strategic pivot. Formerly Expion360, the company has entered the oil-and-gas business through an Eastern Louisiana acquisition involving approximately 3,000 net acres, an existing wellbore and mineral-title research covering roughly 13,000 net acres. The adjusted cash purchase price was approximately $3.425 million.
The company says its exploration agreement contemplates drilling and testing a new lateral well by February 15, 2027, subject to customary exceptions. Expion also plans to commit up to $4 million to leasing activities, including at least $2.5 million for leasing at prevailing market rates. Management is pitching the prospect as a relatively defined entry into upstream energy rather than a blank-sheet exploration program.
The capital strategy is almost as important as the acreage. Expion announced an initial $9 million private placement of 8% convertible debentures and warrants, producing approximately $8.2 million of net proceeds. Investors also have the right, subject to shareholder approval, to invest up to another $91 million. The additional capital is not guaranteed, and the convertible structure introduces potential dilution.
New CEO Kevin Sellers brings an upstream oil-and-gas and investment-banking background, while former CEO Joseph Hammer remains interim Chairman. Hammer described the acquisition as “a drill-ready prospect rather than developing one through extensive and costly exploratory efforts.” The enormous question now is whether XPON can turn its sudden oil-and-gas pivot into an economically successful drilling program while maintaining its legacy energy-storage business.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For further information, please visit 247mnn.com.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.